Asfotase Alfa
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Asfotase Alfa
- Asfotase alfa: From Hypophosphatasia to Mitochondrial Oxidative Phosphorylation Disorder Due to Nuclear DNA Anomalies
Asfotase alfa: From Hypophosphatasia to Mitochondrial Oxidative Phosphorylation Disorder Due to Nuclear DNA Anomalies
One-Sentence Summary
Asfotase alfa is an enzyme replacement therapy originally used to treat hypophosphatasia. The TxGNN model predicts it may be effective for mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies, but no clinical trials and no publications currently support this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypophosphatasia (from the knowledge graph; the Singapore licence records contain no indication text) |
| Predicted New Indication | Mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, asfotase alfa is a recombinant tissue-nonspecific alkaline phosphatase (TNALP) enzyme replacement. It cleaves inorganic pyrophosphate and other phosphate substrates, and its efficacy in hypophosphatasia comes from restoring bone mineralization.
For the predicted indication, no clear mechanistic link can be identified. Nuclear-encoded oxidative phosphorylation disorders arise from defects in respiratory chain subunits or assembly factors. These are not substrates or pathways of TNALP. The high score is a graph-based prediction only and cannot be verified mechanistically with the data compiled for this report.
Other top-ranked predictions show the same pattern: Steel syndrome, exocrine pancreatic insufficiency, Scheie syndrome, Hurler syndrome, lysosomal storage disease with skeletal involvement, familial apolipoprotein C-II deficiency, esophageal varices (with and without bleeding) and cystinosis. None has supporting trials or literature. Their scores likely reflect shared "enzyme replacement" or skeletal-phenotype features in the knowledge graph rather than biological relevance.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN17126P | STRENSIQ Solution for Injection 100 mg/mL | Injection, solution | Not stated in the licence record |
| SIN17127P | STRENSIQ Solution for Injection 40 mg/mL | Injection, solution | Not stated in the licence record |
Both licences are valid single-ingredient products. The manufacturer is Alexion Pharma International Operations Limited, with Patheon Italia S.p.A.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting clinical trials or literature (L5), and no plausible mechanistic link between TNALP replacement and nuclear-encoded respiratory chain defects. Safety label data have not yet been obtained, so the candidate cannot move past initial screening.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA website
- Mechanism of action data for asfotase alfa
- Preclinical or mechanistic evidence linking TNALP activity to mitochondrial oxidative phosphorylation
- Confirmation of the approved indication text for the two Singapore licences
- A route and formulation compatibility assessment (currently injection only)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.